X4 rais­es $27M to take Sanofi’s old drug through piv­otal tri­al

Cam­bridge, MA-based start­up X4 Phar­ma­ceu­ti­cals just bagged $27 mil­lion to take its two lead drugs — one for can­cer, the oth­er for rare dis­ease — to Phase II and III tri­als.

X4 has moved quick­ly. The com­pa­ny emerged in 2015 with a $37.5 mil­lion launch round and an on­col­o­gy as­set it had picked up from Sanofi’s toss pile. The com­pa­ny’s oral, small mol­e­cule drug can­di­dates in­hib­it the bind­ing of chemokine CX­CL12 to CX­CR4, a re­cep­tor-lig­and pair that plays a role in nor­mal im­mune sur­veil­lance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.